Tech Center 1600 • Art Units: 1643 1649 1675
This examiner grants 34% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17784145 | COMPOSITIONS AND METHODS FOR TREATING NEUROMUSCULAR DISORDERS | Non-Final OA | The Regents of the University of California |
| 17790340 | LOOPED PROTEINS COMPRISING CELL PENETRATING PEPTIDES | Non-Final OA | Ohio State Innovation Foundation |
| 17995820 | OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG | Non-Final OA | NOVARTIS AG |
| 17753635 | Management of conditions other than multiple sclerosis in ofatumumab-treated patients | Non-Final OA | Novartis AG |
| 17924461 | PEPTIDE USED TO PREVENT OR TREAT SYNUCLEINOPATHY | Non-Final OA | TOHOKU UNIVERSITY |
| 18278068 | DYNAMIC BIOACTIVE SCAFFOLDS AND THERAPEUTIC USES THEREOF AFTER CNS INJURY | Non-Final OA | Northwestern University |
| 17769705 | EXTRACELLULAR VESICLE-BASED AGENTS AND METHODS FOR THE TREATMENT OF NEUROPATHIC DISORDERS | Non-Final OA | University of Washington |
| 17698636 | WNT COMPOSITIONS AND METHODS FOR SERUM-FREE SYNTHESIS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17908827 | Manipulating Glycogen in Alzheimer's Disease, Epilepsy, Traumatic Brain Injury, and ALS as a Treatment | Final Rejection | University of Kentucky Research Foundation |
| 18168002 | COMBINATION THERAPY WITH SEMAPHORIN-4D BLOCKADE AND HTT-LOWERING AGENT FOR TREATMENT OF HUNTINGTON'S DISEASE | Non-Final OA | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. |
| 17794912 | DETERMINATION AGENT AND DETERMINATION METHOD FOR TAUOPATHY AND DEMENTIA-RELATED DISEASES | Non-Final OA | Sumitomo Pharma Co., Ltd. |
| 18611374 | APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF | Final Rejection | Massachusetts Eye and Ear Infirmary |
| 17801776 | METHODS OF USE OF ANTI-TREM2 ANTIBODIES | Final Rejection | Washington University |
| 17840368 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | Non-Final OA | Washington University |
| 18011965 | PREVENTION OF AXONAL DAMAGE USING ANTIBODY BINDING TO AMYLOID BETA 1-42 | Non-Final OA | Eli Lilly and Company |
| 17883072 | Anti-CGRP Antibody Formulation | Final Rejection | Eli Lilly and Company |
| 17782501 | ENHANCING BLOOD-BRAIN BARRIER DRUG TRANSPORT BY TARGETING ENDOGENOUS REGULATORS | Non-Final OA | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS |
| 17304444 | MICROENCAPSULATED AND CHROMOSOME INTEGRATED COMPOSITIONS FOR L-DOPA MICROBIOME THERAPY | Final Rejection | Iowa State University Research Foundation, Inc. |
| 17509889 | Methods of Reducing Tau in Human Subjects | Non-Final OA | JANSSEN PHARMACEUTICA NV |
| 17105789 | SPINAL CORD INJURY TREATMENT NEUROSPHERE | Final Rejection | KEIO UNIVERSITY |
| 16876353 | EFFICIENT, SCALABLE PRODUCTION OF HUMAN RETINAL PROGENITORS IN VITRO | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17792574 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DEMENTIA | Final Rejection | MITSUBISHI TANABE PHARMA CORPORATION |
| 17757955 | AGENT FOR PREVENTING OR TREATING ACUTE-PHASE NEUROMYELITIS OPTICA | Final Rejection | MITSUBISHI TANABE PHARMA CORPORATION |
| 17793355 | CHIMERIC ANTIGEN RECEPTORS FOR REMOVAL OF AMYLOID | Non-Final OA | University of Tennessee Research Foundation |
| 17762543 | VACCINE THERAPY FOR RAN PROTEIN DISEASES | Final Rejection | University of Florida Research Foundation, Incorporated |
| 17213830 | STEM CELL-DERIVED HUMAN MICROGLIAL CELLS, METHODS OF MAKING AND METHODS OF USE | Non-Final OA | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 18020502 | BECLIN 2 AND USES THEREOF FOR TREATING CANCER AND NEURODEGENERATIVE DISEASES | Non-Final OA | THE METHODIST HOSPITAL SYSTEM |
| 18021566 | PROTEIN, POLYNUCLEOTIDE, VECTOR, HOST CELL, COMPOSITION, METHOD FOR TREATING AN ILLNESS, IN-VITRO METHOD FOR PREDICTING MULTIPLE SCLEROSIS, AND USE OF A PROTEIN OR COMPOSITION | Non-Final OA | Fundação Oswaldo Cruz |
| 16647454 | METHOD FOR AMPLIFYING CONE PHOTORECEPTORS OR ROD PHOTORECEPTORS USING DORSALIZATION SIGNAL TRANSMITTER OR VENTRALIZATION SIGNAL TRANSMITTER | Non-Final OA | RACTHERA CO., LTD. |
| 17596622 | USE OF SRRD IN THE INHIBITION OF PROTEIN AGGREGATION | Final Rejection | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy